Credelio Quattro – which is currently approved and launched only in USA attained the status of blockbuster by notching revenues of USD 100 Million within 8 months of its launch. 100 Million Revenue is the hurdle for attaining Blockbuster Status in Animal Health Industry compared to Human Parma wherein the similar status is attained post sales revenues of USD 1 Billion.
Credelio Quattro – a combination of lotilaner, moxidectin, praziquantel and pyrantel – became Elanco’s fastest pet health blockbuster in its history and one of the industry’s fastest ever, especially with a single geographic approval, reaching blockbuster status of $100 million in net sales in less than eight months.
Credelio Quattro offers the broadest parasite protection available in an isoxazoline endectocide covering six types of parasites—fleas, ticks, heartworm disease, and three risky intestinal parasites—roundworms, hookworms, and tapeworms.
“Credelio Quattro continues to break boundaries when it comes to offering veterinarians and pet owners parasite protection,” said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco.
“We’re seeing incredibly strong demand for all-in-one products from pet owners and veterinarians alike. In fact, Credelio Quattro captured approximately 14% of the dollar share in broad-spectrum sales out of U.S. veterinary clinics in June 2025. The introduction of Credelio Quattro has bolstered our broader Elanco portfolio in U.S. veterinary clinics, with Elanco now offering veterinarians a complete ecto, endo, and endecto portfolio with a variety of parasite coverage at a variety of price points to meet veterinarian and pet owner needs.”
Human and pet cases of tickborne disease, such as Lyme disease which is spread by the black-legged tick, are on the rise. According to the Companion Animal Parasite Council (CAPC), black-legged ticks are found across much of the eastern half of the United States, with aggressive populations in the North that appear to pose a higher risk of transmitting Lyme disease to humans and dogs; and these populations are also spreading South and West in the United States, as well as northward into new areas of Canada.
Multiple studies have shown that areas of high risk for dogs are the same areas that humans are most likely to test positive for Lyme disease as well. CAPC recommends using products on pets that repel or quickly kill ticks before pathogens are transmitted. Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) also contains lotilaner that kills ticks faster than sarolaner in Simparica Trio® and afoxolaner in NexGard®, protecting dogs against pathogen-carrying ticks as per company data.
Credelio Quattro joins Experior® as Elanco’s second of six recently launched blockbuster-potential products to reach the blockbuster milestone of $100 million annual net sales. Elanco continues to prepare to take Credelio Quattro global, with numerous submissions made in Australia, Canada, the EU, the UK, and Japan, setting up the company’s expected geographic expansion for the product starting in 2026.
